Vitamin K2 Supplementation in Adult Episodic Migraine
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial
| Condition(s) | Migraine Headache, Arterial Stiffness, Vitamin K Deficiency |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on |
| Who can participate | Inclusion Criteria: * Adults aged 18 years or above * History of episodic migraine with or without aura since \> 12 months according to the ICHD-3 criteria. * Migraine frequency from 4-14 days per month over the 3 months prior to screening. * Migraine frequency from 4-14 days per month during the baseline period of assessment. * Successful completion of the migraine diary during the baseline evaluation period. Exclusion Criteria: * Migraine patients with superimposed tension type or other forms of primary headaches * Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan) * Patients who have been on any of the previously listed medications within |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Sola Aoun Bahous, M.D. Ph.D. |
| Locations | Beirut, Beirut, Lebanon |
| Start date | 2024-03-06 |
| NCT ID | NCT05943457 |
| Official listing | https://clinicaltrials.gov/study/NCT05943457 |